Research priorities for the development and implementation of serological tools for malaria surveillance

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Elliott, Salenna R ^a   Fowkes, Freya J I ^a,b,c   Richards, Jack S ^a,b,c   Reiling, Linda ^a   Drew, Damien R ^a   Beeson, James G ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BIOLOGICAL MARKER;

ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SURVEILLANCE; HEALTH SERVICE; HIGH THROUGHPUT SCREENING; HUMAN; LONG TERM EXPOSURE; LONGEVITY; MALARIA; MALARIA CONTROL; NON INVASIVE PROCEDURE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POINT OF CARE TESTING; PREVALENCE; PROGRAM DEVELOPMENT; RESEARCH PRIORITY; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY;

EID: 84912017370     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-100     Document Type: Article

References (108)

1. Greenwood BM: Control to elimination: implications for malaria research. Trends Parasitol 2008, 24:449-54.
2. World Health Organization: World Malaria Report 2012. Geneva; 2012.
3. Snow RW, Marsh K: Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet 2010, 376:137-9.
4. O'Meara WP, Mangeni JN, Steketee R, Greenwood B: Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2010, 10:545-55.
5. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford Anthony JC, Sesay Sanie SS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA, Whittle HC, Greenwood BM, Conway DJ: Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 2008, 372:1545-54.
6. Okiro EA, Alegana VA, Noor AM, Snow RW: Changing malaria intervention coverage, transmission and hospitalization in Kenya. Malar J 2010, 9:285.
7. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, Carneiro I, Malima R, Lusingu J, Manjurano A, NkyaWMM, Lemnge MM, Cox J, Reyburn H, Riley EM: Estimating medium-and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci USA 2005, 102:5108-13.
8. Corran P, Coleman P, Riley E, Drakeley C: Serology: a robust indicator of malaria transmission intensity? Trends Parasitol 2007, 23:575-82.
9. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ: Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 2012, 3:1237.
10. Drakeley C, Cook J: Chapter 5. Potential contribution of seroepidemiological analysis for monitoring malaria control and elimination: historical and current perspectives. Adv Parasitol 2009, 69:299-352.
11. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, Masika P, Mosha J, Bousema T, Shekalaghe S, Cook J, Corran P, Ghani A, Riley EM, Drakeley C: Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS ONE 2009, 4:e6083.
12. Bousema T, Drakeley C, Gesase S, Hashim R, Magesa S, Mosha F, Otieno S, Carneiro I, Cox J, Msuya E, Kleinschmidt I, Maxwell C, Greenwood B, Riley E, Sauerwein R, Chandramohan D, Gosling R: Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 2010, 201:1764-74.
13. Badu K, Afrane YA, Larbi J, Stewart VA, Waitumbi J, Angov E, Ong'echa JM, Perkins DJ, Zhou G, Githeko A, Yan G: Marked variation in MSP-119 antibody responses to malaria in western Kenyan highlands. BMC Infect Dis 2012, 12:50.
14. Cook J, Kleinschmidt I, Schwabe C, Nseng G, Bousema T, Corran PH, Riley EM, Drakeley CJ: Serological markers suggest heterogeneity of effectiveness of malaria control interventions on Bioko Island, equatorial Guinea. PLoS ONE 2011, 6:e25137.
15. Cook J, Reid H, Iavro J, Kuwahata M, Taleo G, Clements A, McCarthy J, Vallely A, Drakeley C: Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J 2010, 9:169.
16. Hsiang MS, Hwang J, Kunene S, Drakeley C, Kandula D, Novotny J, Parizo J, Jensen T, Tong M, Kemere J, Dlamini S, Moonen B, Angov E, Dutta S, Ockenhouse C, Dorsey G, Greenhouse B: Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS ONE 2012, 7:e29550.
17. Satoguina J,Walther B, Drakeley C, Nwakanma D, Oriero EC, Correa S, Corran P, Conway DJ, Walther M: Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J 2009, 8:274.
18. Sturrock Hugh JW, Hsiang MS, Cohen JM, Smith DL, Greenhouse B, Bousema T, Gosling RD: Targeting asymptomatic malaria infections: active surveillance in control and elimination. PLoS Med 2013, 10:e1001467.
19. Cotter C, Sturrock Hugh JW, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem Richard GA: The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 2013, 382:900-11.
20. Okell LC, Ghani AC, Lyons E, Drakeley CJ: Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis 2009, 200:1509-17.
21. Erhart A, Thang ND, Bien TH, Tung NM, Hung NQ, Hung LX, Tuy TQ, Speybroeck N, Cong LD, Coosemans M, D'Alessandro U: Malaria epidemiology in a rural area of theMekongDelta: a prospective community-based study. Trop Med Int Health 2004, 9:1081-90.
22. Richards JS, Beeson JG: The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009, 87:377-90.
23. Beeson JG, Fowkes FJI, Reiling L, Osier FH, Drew DR, Brown GV: Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research. In: Malaria Vaccine Development: Over 40 Years of Trials and Tribulations. edn. Edited by Giampietro C, Howard E: Future Medicine Ltd; 2014: 81-104.
24. Doderer-Lang C, Atchade PS, Meckert L, Haar E, Perrotey S, Filisetti D, Aboubacar A, Pfaff AW, Brunet J, Chabi NW, Akpovi CD, Anani L, Bigot A, Sanni A, Candolfi E: The ears of the African elephant: unexpected high seroprevalence of Plasmodium ovale and Plasmodium malariae in healthy populations in Western Africa. Malar J 2014, 13:240.
25. Doolan DL: Plasmodium immunomics. Int J Parasitol 2011, 41:3-20.
26. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, Molina DM, Burk CR, Waisberg M, Jasinskas A, Tan X, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang X, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner PL, Pierce SK: A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA 2010, 107:6958-63.
27. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair PL, Aguiar JC, Baldi P, Davies DH, Felgner PL: Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008, 8:4680-94.
28. Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes Freya JI, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG: Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013, 191:795-809.
29. Osier Faith HA, Fegan G, Polley SD, Murungi L, Verra F, Tetteh Kevin K A, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K: Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008, 76:2240-8.
30. Igonet S, Vulliez-Le Normand B, Faure G, Riottot M, Kocken Clemens HM, Thomas AW, Bentley GA: Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation. J Mol Biol 2007, 366:1523-37.
31. Woodberry T, Minigo G, Piera KA, Hanley JC, de Silva, Harini D, Salwati E, Kenangalem E, Tjitra E, Coppel RL, Price RN, Anstey NM, Plebanski M: Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: speciesspecific and cross-reactive responses. J InfectDis 2008, 198:134-42.
32. Cochrane AH, Nardin EH, Arruda M de, Maracic M, Clavijo P, Collins WE, Nussenzweig RS: Widespread reactivity of human sera with a variant repeat of the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg 1990, 43:446-51.
33. Tran TM, Oliveira-Ferreira J, Moreno A, Santos F, Yazdani SS, Chitnis CE, Altman JD, Meyer EV, Barnwell JW, Galinski MR: Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am J Trop Med Hyg 2005, 73:244-55.
34. Cole-Tobian JL, Michon P, Biasor M, Richards JS, Beeson JG, Mueller I, King CL: Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun 2009, 77:4009-17.
35. Fowkes Freya JI, Richards JS, Simpson JA, Beeson JG: The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 2010, 7:e1000218.
36. Richards JS, Stanisic DI, Fowkes Freya JI, Tavul L, Dabod E, Thompson JK, Kumar S, Chitnis CE, Narum DL, Michon P, Siba PM, Cowman AF, Mueller I, Beeson JG: Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 2010, 51:e50-60.
37. Reiling L, Richards JS, Fowkes Freya JI, Barry AE, Triglia T, Chokejindachai W, Michon P, Tavul L, Siba PM, Cowman AF, Mueller I, Beeson JG: Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol 2010, 185:6157-67.
38. RTSS Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo Barbara Gaelle Nfono Ondo, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, et al.: A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367:2284-95.
39. Fowkes Freya JI, Simpson JA, Beeson JG: Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. BMC Med 2013, 11:232.
40. Thomas AW, Trape JF, Rogier C, Goncalves A, Rosario VE, Narum DL: High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg 1994, 51:730-40.
41. Polley SD, Mwangi T, Kocken Clemens HM, Thomas AW, Dutta S, Lanar DE, Remarque E, Ross A, Williams TN, Mwambingu G, Lowe B, Conway DJ, Marsh K: Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004, 23:718-28.
42. Chelimo K, Ofulla AV, Narum DL, Kazura JW, Lanar DE, John CC: Antibodies to Plasmodium falciparum antigens vary by age and antigen in children in a malaria-holoendemic area of Kenya. Pediatr Infect Dis J 2005, 24:680-4.
43. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois M, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, et al.: A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011, 365:1004-13.
44. Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J, Noor AM, Snow RW, Drakeley C: Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008. Emerging Infect Dis 2010, 16:392-9.
45. Cook J, Speybroeck N, Sochanta T, Somony H, Sokny M, Claes F, Lemmens K, Theisen M, Soares IS, D'Alessandro U, Coosemans M, Erhart A: Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia. Malar J 2012, 11:86.
46. John CC, Zickafoose JS, Sumba PO, King CL, Kazura JW: Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liverstage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003, 71:4320-5.
47. Noland GS, Hendel-Paterson B, Min XM, Moormann AM, Vulule JM, Narum DL, Lanar DE, Kazura JW, John CC: Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission. Infect Immun 2008, 76:5721-8.
48. Webster HK, Gingrich JB, Wongsrichanalai C, Tulyayon S, Suvarnamani A, Sookto P, Permpanich B: Circumsporozoite antibody as a serologic marker of Plasmodium falciparum transmission. Am J Trop Med Hyg 1992, 47:489-97.
49. Campo JJ, Whitman TJ, Freilich D, Burgess TH, Martin GJ, Doolan DL: Toward a surrogate marker of malaria exposure: modeling longitudinal antibody measurements under outbreak conditions. PLoS ONE 2011, 6:e21826.
50. Mugyenyi CK, Elliott SR, McCallum FJ, Anders RF, Marsh K, Beeson JG: Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in humanmalaria. PLoS ONE 2013, 8:e68304.
51. Ouédraogo AL, Roeffen W, Luty Adrian JF, de Vlas, Sake J, Nebie I, Ilboudo-Sanogo E, Cuzin-Ouattara N, Teleen K, Tiono AB, Sirima SB, Verhave J, Bousema T, Sauerwein R: Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission. Infect Immun 2011, 79:4957-64.
52. Bousema JT, Drakeley CJ, Sauerwein RW: Sexual-stage antibody responses to P. falciparum in endemic populations. Curr Mol Med 2006, 6:223-9.
53. Bousema JT, Roeffen W, van der Kolk, Mike de Vlas, Sake J, van de Vegte-Bolmer Marga, Bangs MJ, Teelen K, Kurniawan L, Maguire JD, Baird JK, Sauerwein RW: Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in papua, indonesia. Am J Trop Med Hyg 2006, 74:425-31.
54. Marrelli MT, Malafronte RS, Kloetzel JK: Seasonal variation of anti-Plasmodium falciparum antibodies directed against a repetitive peptide of gametocyte antigen pfs2400 in inhabitants in the State of Amapá, Brazil. Acta Trop 1997, 63:167-77.
55. Salanti A, Staalsoe T, Lavstsen T, Jensen Anja TR, Sowa MP Kordai, Arnot DE, Hviid L, Theander TG: Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancyassociated malaria. Mol Microbiol 2003, 49:179-91.
56. Fowkes Freya JI, McGready R, Cross NJ, Hommel M, Simpson JA, Elliott SR, Richards JS, Lackovic K, Viladpai-Nguen J, Narum D, Tsuboi T, Anders RF, Nosten F, Beeson JG: New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis 2012, 206:1612-21.
57. Baum E, Badu K, Molina DM, Liang X, Felgner PL, Yan G: Protein microarray analysis of antibody responses to Plasmodium falciparum in western Kenyan highland sites with differing transmission levels. PLoS ONE 2013, 8:e82246.
58. Ramasamy R, Nagendran K, Ramasamy MS: Antibodies to epitopes on merozoite and sporozoite surface antigens as serologic markers of malaria transmission: studies at a site in the dry zone of Sri Lanka. Am J Trop Med Hyg 1994, 50:537-47.
59. Lee KN, Suh IB, Chang EA, Kim SD, Cho NS, Park PW, An Seong Soo A, Park O, Lim C: Prevalence of antibodies to the circumsporozite protein of Plasmodium vivax in five different regions of Korea. Trop Med Int Health 2003, 8:1062-7.
60. Lim CS, Yoon JK, Chang EA, Suh IB, An Seong Soo A, Lee K, Chung JT, Tockgo YC: Seroprevalence to the circumsporozoite protein peptide antigen of Plasmodium vivax in Korean children. Microbiol Immunol 2005, 49:521-7.
61. Mendis C, Del Giudice G, Gamage-Mendis AC, Tougne C, Pessi A, Weerasinghe S, Carter R, Mendis KN: Anti-circumsporozoite protein antibodies measure age related exposure to malaria in Kataragama, Sri Lanka. Parasite Immunol 1992, 14:75-86.
62. Culleton R, Ndounga M, Zeyrek FY, Coban C, Casimiro PN, Takeo S, Tsuboi T, Yadava A, Carter R, Tanabe K: Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J Infect Dis 2009, 200:1465-9.
63. The malERA Consultative Group on Monitoring Evaluation and Surveillance: A research agenda formalaria eradication:monitoring, evaluation, and surveillance. PLoS Med 2011, 8:e1000400.
64. The malERA Consultative Group on Diagnoses and Diagnostics: A research agenda for malaria eradication: diagnoses and diagnostics. PLoS Med 2011, 8:e1000396.
65. Badu K, Siangla J, Larbi J, Lawson BW, Afrane Y, Ong'echa J, Remoue F, Zhou G, Githeko AK, Yan G: Variation in exposure to Anopheles gambiae salivary gland peptide (gSG6-P1) across different malaria transmission settings in the western Kenya highlands. Malar J 2012, 11:318.
66. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander T, Ronca R, Modiano D, Arcà B, Drakeley C: IgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS ONE 2012, 7:e40170.
67. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, Doumbo S, Doumtabe D, Kone Y, Huang C, Doumbo OK, Miller LH, Long CA, Pierce SK: In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun 2010, 78:737-45.
68. Wilson DW, Fowkes Freya JI, Gilson PR, Elliott SR, Tavul L, Michon P, Dabod E, Siba PM, Mueller I, Crabb BS, Beeson JG: Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans. PLoS ONE 2011, 6:e27705.
69. Joos C, Marrama L, Polson Hannah EJ, Corre S, Diatta A, Diouf B, Trape J, Tall A, Longacre S, Perraut R: Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS ONE 2010, 5:e9871.
70. Reiling L, Richards JS, Fowkes Freya JI, Wilson DW, Chokejindachai W, Barry AE, Tham W, Stubbs J, Langer C, Donelson J, Michon P, Tavul L, Crabb BS, Siba PM, Cowman AF, Mueller I, Beeson JG: The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS ONE 2012, 7:e45253.
71. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG: Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 2014, 12:108.
72. Persson Kristina EM, Fowkes Freya JI, McCallum FJ, Gicheru N, Reiling L, Richards JS, Wilson DW, Lopaticki S, Cowman AF, Marsh K, Beeson JG: Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity. J Immunol 2013, 191:785-94.
73. Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, Huang C, Li S, Doumbo S, Doumtabe D, Kone Y, Bathily A, Dia S, Niangaly M, Dara C, Sangala J, Miller LH, Doumbo OK, Kayentao K, Long CA, Miura K, Wright GJ, Traore B, Crompton PD: Naturally acquired antibodies specific for Plasmodium falciparum reticulocytebinding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis 2014, 209:789-98.
74. Hill DL, Eriksson EM, Li Wai Suen, Connie SN, Chiu CY, Ryg-Cornejo V, Robinson LJ, Siba PM, Mueller I, Hansen DS, Schofield L: Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS ONE 2013, 8: e74627.
75. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M: Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low-and middle-income countries. PLoS Med 2012, 9:e1001306.
76. Heymann DL, Brilliant L: Surveillance in eradication and elimination of infectious diseases: a progression through the years. Vaccine 2011, 29(Suppl 4):D141-4.
77. Rodriguez-del Valle M, Quakyi IA, Amuesi J, Quaye JT, Nkrumah FK, Taylor DW: Detection of antigens and antibodies in the urine of humans with Plasmodium falciparum malaria. J Clin Microbiol 1991, 29:1236-42.
78. Estévez PT, Satoguina J, Nwakanma DC, West S, Conway DJ, Drakeley CJ: Human saliva as a source of anti-malarial antibodies to examine population exposure to Plasmodium falciparum. Malar J 2011, 10:104.
79. Chidi AP, Chishimba S, Kobayashi T, Hamapumbu H, Mharakurwa S, Thuma PE, Moss WJ: Validation of oral fluid samples to monitor serological changes to Plasmodium falciparum: an observational study in southern Zambia. Malar J 2011, 10:162.
80. Siegrist C, Aspinall R: B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-94.
81. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K: IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J 2007, 6:82.
82. Akpogheneta OJ, Duah NO, Tetteh Kevin KA, Dunyo S, Lanar DE, Pinder M, Conway DJ: Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun 2008, 76:1748-55.
83. Portugal S, Pierce SK, Crompton PD: Young lives lost as B cells falter: what we are learning about antibody responses in malaria. J Immunol 2013, 190:3039-46.
84. Weiss GE, Traore B, Kayentao K, Ongoiba A, Doumbo S, Doumtabe D, Kone Y, Dia S, Guindo A, Traore A, Huang C, Miura K, Mircetic M, Li S, Baughman A, Narum DL, Miller LH, Doumbo OK, Pierce SK, Crompton PD: The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog 2010, 6:e1000912.
85. Chu VT, Berek C: The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 2013, 251:177-88.
86. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, Kayentao K, Ongoiba A, Doumbo OK, Pierce SK: Atypical memory B cells are greatly expanded in individuals living in a malariaendemic area. J Immunol 2009, 183:2176-82.
87. Illingworth J, Butler NS, Roetynck S, Mwacharo J, Pierce SK, Bejon P, Crompton PD, Marsh K, Ndungu FM: Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol 2013, 190:1038-47.
88. Scholzen A, Sauerwein RW: How malaria modulates memory: activation and dysregulation of B cells in Plasmodium infection. Trends Parasitol 2013, 29:252-62.
89. Nduati E, Gwela A, Karanja H, Mugyenyi C, Langhorne J, Marsh K, Urban BC: The plasma concentration of the B cell activating factor is increased in children with acute malaria. J Infect Dis 2011, 204:962-70.
90. Modiano D, Petrarca V, Sirima BS, Nebié I, Diallo D, Esposito F, Coluzzi M: Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci USA 1996, 93:13206-11.
91. Dolo A, Modiano D, Maiga B, Daou M, Dolo G, Guindo H, Ba M, Maiga H, Coulibaly D, Perlman H, Blomberg MT, Touré YT, Coluzzi M, Doumbo O: Difference in susceptibility to malaria between two sympatric ethnic groups in Mali. Am J Trop Med Hyg 2005, 72:243-8.
92. Bolad A, Farouk SE, Israelsson E, Dolo A, Doumbo OK, Nebié I, Maiga B, Kouriba B, Luoni G, Sirima BS, Modiano D, Berzins K, Troye-Blomberg M: Distinct interethnic differences in immunoglobulin G class/subclass and immunoglobulin M antibody responses to malaria antigens but not in immunoglobulin G responses to nonmalarial antigens in sympatric tribes living in West Africa. Scand J Immunol 2005, 61:380-6.
93. Portugal S, Doumtabe D, Traore B, Miller LH, Troye-Blomberg M, Doumbo OK, Dolo A, Pierce SK, Crompton PD: B cell analysis of ethnic groups in Mali with differential susceptibility to malaria. Malar J 2012, 11:162.
94. Pratt-Riccio LR, Lima-Junior JC, Carvalho Leonardo JM, Theisen M, Espíndola-Mendes EC, Santos F, Oliveira-Ferreira J, Goldberg AC, Daniel-Ribeiro CT, Banic DM: Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria. Am J Trop Med Hyg 2005, 73:1096-103.
95. Rosenberg R, Wirtz RA: Intrinsic individual differences in circumsporozoite antibody response at a hyperendemic malaria focus. Trans R Soc Trop Med Hyg 1990, 84:206-8.
96. Razakandrainibe R, Thonier V, Ratsimbasoa A, Rakotomalala E, Ravaoarisoa E, Raherinjafy R, Andrianantenaina H, Voahanginirina O, Rahasana TE, Carod JF, Domarle O, Menard D: Epidemiological situation of malaria in Madagascar: baseline data for monitoring the impact of malaria control programmes using serological markers. Acta Trop 2009, 111:160-7.
97. Mount AM, Mwapasa V, Elliott SR, Beeson JG, Tadesse E, Lema VM, Molyneux ME, Meshnick SR, Rogerson SJ: Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004, 363:1860-7.
98. Flateau C, Le Loup G, Pialoux G: Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 2011, 11:541-56.
99. Fillol F, Sarr JB, Boulanger D, Cisse B, Sokhna C, Riveau G, Simondon KB, Remoué F: Impact of child malnutrition on the specific anti-Plasmodium falciparum antibody response. Malar J 2009, 8:116.
100. Genton B, Al-Yaman F, Ginny M, Taraika J, Alpers MP: Relation of anthropometry to malaria morbidity and immunity in Papua New Guinean children. Am J Clin Nutr 1998, 68:734-41.
101. Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, Liewsaree W, Riley EM, Hafalla Julius Clemence R: Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 2010, 6:e1000770.
102. Amanna IJ, Slifka MK: Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-38.
103. Hoffman SL, Rogers WO, Carucci DJ, Venter JC: From genomics to vaccines: malaria as a model system. Nat Med 1998, 4:1351-3.
104. Langhorne J, Albano FR, Hensmann M, Sanni L, Cadman E, Voisine C, Sponaas A: Dendritic cells, pro-inflammatory responses, and antigen presentation in a rodent malaria infection. Immunol Rev 2004, 201:35-47.
105. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG: Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009, 77:1165-74.
106. Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, Wedgwood RJ: The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988, 112:634-40.
107. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, Ghani AC: Dynamics of the Antibody Response to Plasmodium falciparum Infection in African Children. J Infect Dis 2014.
108. The malERA Consultative Group on Health Systems and Operational Research: A research agenda for malaria eradication: health systems and operational research. PLoS Med 2011, 8:e1000397.